Functional improvement of dystrophic muscle by myostatin blockade
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Mice and cattle with mutations in the myostatin (GDF8) gene show a marked increase in body weight and muscle mass, indicating that this new member of the TGF-beta superfamily is a negative regulator of skeletal muscle growth. Inhibition of the myostatin gene product is predicted to increase muscle mass and improve the disease phenotype in a variety of primary and secondary myopathies. We tested the ability of inhibition of myostatin in vivo to ameliorate the dystrophic phenotype in the mdx mouse model of Duchenne muscular dystrophy (DMD). Blockade of endogenous myostatin by using intraperitoneal injections of blocking antibodies for three months resulted in an increase in body weight, muscle mass, muscle size and absolute muscle strength in mdx mouse muscle along with a significant decrease in muscle degeneration and concentrations of serum creatine kinase. The functional improvement of dystrophic muscle by myostatin blockade provides a novel, pharmacological strategy for treatment of diseases associated with muscle wasting such as DMD, and circumvents the major problems associated with conventional gene therapy in these disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The interest in myostatin was generated by recent studies where antibodies for myostatin were created and administered to adult rodents, which resulted in an increase in body mass, muscle mass, muscle size, and strength [11,12].”
From Effects of methoxyisoflavone, ecdysterone, and sulfo-polysaccharide supplementation on training adaptations in resistance-trained males (2006) · cites this paper as [12]
Citations
Cites
Textbook of Medical Physiology
(1966) · Annals of Internal Medicine · doi:10.7326/0003-4819-64-6-1363_2 · Cited by 9,749
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
TEXTBOOK OF MEDICAL PHYSIOLOGY
GUYTON, A. C. (1967) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196701000-00031 · Cited by 2,837
Dystrophin expression in the mdx mouse restored by stem cell transplantation
Gussoni, E., Soneoka, Y., Strickland, C. D., Buzney, E. A., Khan, M. K., Flint, A. F., Kunkel, L. M., & Mulligan, R. C. (1999) · Nature · doi:10.1038/43919 · Cited by 1,802 · cited 1×
“In comparison with conventional transgenic, cell and gene therapy approache”
BackgroundX chromosome-linked muscular dystrophy (mdx) in the mouse
Bulfield, G., Siller, W. G., Wight, P. A., & Moore, K. J. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.4.1189 · Cited by 1,765
Regulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616 · cited 1×
“Alterations in Smad 2 and 3 phosphorylation would be predicted to regulate the formation of Smad complexes, their nuclear translocation and transcriptional regulation of genes associated with commitment of muscle progenitor”
BackgroundA deletion in the bovine myostatin gene causes the double–muscled phenotype in cattle
Grobet, L., Royo Martin, L. J., Poncelet, D., Pirottin, D., Brouwers, B., Riquet, J., Schoeberlein, A., Dunner, S., Ménissier, F., Massabanda, J., et al. (1997) · Nature Genetics · doi:10.1038/ng0997-71 · Cited by 1,556
Dystrophin protects the sarcolemma from stresses developed during muscle contraction
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., & Sweeney, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3710 · Cited by 1,526 · cited 1×
“The regimen did not completely reverse dystrophic changes; physiological parameters evaluated by ex vivo tests, such as susceptibility to damage by lengthening contraction”
BackgroundAhima, R. S., & Flier, J. S. (2000) · Annual Review of Physiology · doi:10.1146/annurev.physiol.62.1.413 · Cited by 1,428
Self-citation
Research works printed but not linked: 2
- Jalenak, M. et al. Transcriptional changes arising from in vivo inhibition of myostatin. J. Neurol. Sci. 199 (suppl)., S83 (2002)
- Engel, A. G. & Franzini-Armstrong, C. Myology (McGraw-Hill, New York, 1994)
Cited by
Items 301–400 of 853
Ins and outs of therapy in limb girdle muscular dystrophies
Danièle, N., Richard, I., & Bartoli, M. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.02.005 · Cited by 64
Singh, R., Braga, M., Reddy, S. T., Lee, S.-J., Parveen, M., Grijalva, V., Vergnes, L., & Pervin, S. (2017) · Endocrinology · doi:10.1210/en.2016-1607 · Cited by 54
“The inhibition of TGF-b signaling has shown promise for treatment of muscle disorders (25, 36, 37).”
BackgroundDual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy
Kemaladewi, D. U., Hoogaars, W. M. H., van Heiningen, S. H., Terlouw, S., de Gorter, D. J. J., den Dunnen, J. T., van Ommen, G. J. B., Aartsma-Rus, A. M., ten Dijke, P., & Hoen, P. A. C. ’. (2011) · BMC Medical Genomics · doi:10.1186/1755-8794-4-36 · Cited by 54
“Several strategies to block myostatin such as neutralizing antibodies [28-30], overexpression of its inhibitory propeptide [31-34], or administration of soluble AcvRIIB [35] induced increases in muscle mass and force and reduced fibrosis in the mdx mice [36].”
BackgroundMichel, R. N., Chin, E. R., Chakkalakal, J. V., Eibl, J. K., & Jasmin, B. J. (2007) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h07-093 · Cited by 55
“Treatment of mdx mice with an anti-myostatin mouse monoclonal antibody results in an increase in muscle mass, an increase in fibre cross-sectional area, a decrease in fibre size variability, decreased cellular infiltration, and increased contractile force (Bogdanovich et al. 2002).”
BackgroundMyostatin gene promoter: structure, conservation and importance as a target for muscle modulation
Grade, C. V. C., Mantovani, C. S., & Alvares, L. E. (2019) · Journal of Animal Science and Biotechnology/Journal of animal science and biotechnology · doi:10.1186/s40104-019-0338-5 · Cited by 58
Reiter, M., Walf-Vorderwülbecke, V., Christians, A., Pfaffl, M. W., & Meyer, H. H. D. (2006) · Analytica Chimica Acta · doi:10.1016/j.aca.2006.10.049 · Cited by 58
Xu, R., deVries, S., Camboni, M., & Martin, P. T. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080967 · Cited by 57
Benabdallah, B. F., Bouchentouf, M., Rousseau, J., Bigey, P., Michaud, A., Chapdelaine, P., Scherman, D., & Tremblay, J. P. (2008) · Cell Transplantation · doi:10.3727/096368908784153913 · Cited by 51
Antimyostatin Treatment in Health and Disease: The Story of Great Expectations and Limited Success
Nielsen, T. L., Vissing, J., & Krag, T. O. B. (2021) · Cells · doi:10.3390/cells10030533 · Cited by 60
“Bogdanovich et al. were the first to successfully treat the commonly used mouse model of Duchenne Muscular Dystrophy (DMD), the mdx, with antibodies directed towards myostatin (monoclonal antibodies, JA16) [73].”
InfluentialSelf-citationMyotonic Dystrophy: Therapeutic Strategies for the Future
Wheeler, T. M. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.08.001 · Cited by 62
“function, and reduces dystrophic changes in a mouse model of dystrophin-deficient muscular dystrophy.(35,36)”
BackgroundTherapeutics in Duchenne muscular dystrophy
Strober, J. B. (2006) · NeuroRx · doi:10.1016/j.nurx.2006.01.005 · Cited by 53
“In the mdx mouse, blocking myostatin by injecting blocking antibodies lead to an increase in body weight as well as muscle mass, size and strength.(61) When the mdx mouse was crossed with mice with a myostatin null mutation, the mdx mice that were homozygous for the myostatin mutation were larger and DUCHENNE MUSCULAR…”
Kim, Y. S., Bobbili, N., Paek, K. S., & Jin, H. (2006) · Poultry Science · doi:10.1093/ps/85.6.1062 · Cited by 66
“Immunoneutralization of myostatin as a potential approach to improve skeletal muscle growth has been demonstrated in laboratory animals (Bogdanovich et al., 2002; Whittemore et al., 2003).”
BackgroundInfluentialKhalafi, M., Aria, B., Symonds, M. E., & Rosenkranz, S. K. (2023) · Physiology & Behavior · doi:10.1016/j.physbeh.2023.114272 · Cited by 59
Bish, L. T., Sleeper, M. M., Forbes, S. C., Morine, K., Reynolds, C., Singletary, G. E., Trafny, D. J., Pham, J., Bogan, J. R., Kornegay, J. N., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.102 · Cited by 56
“Other investigators have developed systemic myostatin inhibition strategies based on injection of anti-myostatin antibodies (Bogdanovich et al. , 2002; Wagner et al. , 2008) and soluble activin IIB receptor protein (Pistilli et al. , 2011).”
Myostatin inhibition: a potential performance enhancement strategy?
Fedoruk, M. N., & Rupert, J. L. (2008) · Scandinavian Journal of Medicine & Science in Sports · doi:10.1111/j.1600-0838.2007.00759.x · Cited by 49
“Injection of anti-myostatin antibodies into young adult mdx mice (a murine model of muscular dystrophy) caused muscle hypertrophy, an increase in both total mass and percent muscle mass, and an increase in both overall strength and force production in isolated muscle (Bogdanovich et al., 2002).”
BackgroundSwanson, D. L., Sabirzhanov, B. E., VandeZande, A., & Clark, T. G. (2009) · Physiological and Biochemical Zoology · doi:10.1086/591099 · Cited by 56
Centronuclear myopathies under attack: A plethora of therapeutic targets
Tasfaout, H., Cowling, B. S., & Laporte, J. (2018) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-180309 · Cited by 52
“gene delivery of follistatin and homologues 772 [135], myostatin propeptide [141, 142], myostatin 773 antibodies [136] and more recently a soluble form 774”
BackgroundSkeletal Muscle Regeneration by the Exosomes of Adipose Tissue-Derived Mesenchymal Stem Cells
Byun, S., Sim, C., Chung, Y., Kim, H. K., Park, S., Kim, H. K., Cho, S., & Lee, S. (2021) · Current Issues in Molecular Biology · doi:10.3390/cimb43030104 · Cited by 54
“Despite the promising results of a few trials [6,7], the lack of functional improvement and unexpected complications has prevented the clinical use of these drugs in muscle regeneration [3–5].”
ResultStem cell therapy for muscular dystrophy
Sohn, R. L., & Gussoni, E. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.1.1 · Cited by 53
“Myostatin is another factor which has been shown to signal satellite cell quiescence and serve as a potent negative regulator of satellite cell activation [84]; neutralising antibodies for myostatin have been injected in mdx mice and shown to decrease muscle degeneration and thus improve function [85].”
BackgroundTobin, J. F., & Celeste, A. J. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.03.016 · Cited by 50
Dysferlin and Animal Models for Dysferlinopathy
Kobayashi, K., Izawa, T., Kuwamura, M., & Yamate, J. (2012) · Journal of Toxicologic Pathology · doi:10.1293/tox.25.135 · Cited by 52
Treating cancer cachexia to treat cancer
Lee, S.-J., & Glass, D. J. (2011) · Skeletal Muscle · doi:10.1186/2044-5040-1-2 · Cited by 50
“systemically to adult mice [12-15].”
Bhattacharya, I., Pawlak, S., Marraffino, S., Christensen, J., Sherlock, S. P., Alvey, C., Morris, C., Arkin, S., & Binks, M. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.386 · Cited by 50
IRE1α regulates skeletal muscle regeneration through myostatin mRNA decay
He, S., Fu, T., Yu, Y., Liang, Q., Li, L., Liu, J., Zhang, X., Zhou, Q., Guo, Q., Xu, D., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143737 · Cited by 54
“Moreover, inhibition of myostatin has been shown to improve the hallmarks of the muscular dystrophy in mdx mice (56, 57).”
BackgroundPre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview.
Luca, A. D. (2012) · Europe PMC (PubMed Central) · Cited by 49
A Mouse Model for Dominant Collagen VI Disorders
Pan, T., Zhang, R.-Z., Arita, M., Bogdanovich, S., Adams, S. M., Gara, S. K., Wagener, R., Khurana, T. S., Birk, D. E., & Chu, M.-L. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.549311 · Cited by 50
“Physiological Analysis—Physiological studies were performed using female mice by methods described previously (28, 29).”
MethodSelf-citationNuclear Function of Smad7 Promotes Myogenesis
Miyake, T., Alli, N. S., & McDermott, J. C. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01005-09 · Cited by 54
Understanding the muscular dystrophy caused by deletion of choline kinase beta in mice
Wu, G., Sher, R. B., Cox, G. A., & Vance, D. E. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.02.006 · Cited by 52
“Myostatin is amember of the transforming growth factor-β superfamily that acts as a negative regulator of skeletalmusclemass [28,50–52].”
BackgroundCardiac Consequences to Skeletal Muscle-Centric Therapeutics for Duchenne Muscular Dystrophy
Townsend, D., Yasuda, S., Chamberlain, J. S., & Metzger, J. M. (2009) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2009.04.006 · Cited by 49
“2007), myostatin-inhibiting agents (Bogdanovich et al. 2002), drugs that increase aberrant stop codon read-through (Welch et al.”
BackgroundTreatment options for Duchenne muscular dystrophy
Ciafaloni, E., & Moxley, R. T. (2008) · Current Treatment Options in Neurology · doi:10.1007/s11940-008-0010-4 · Cited by 47
“muscle mass, increased grip force, and decreased dystrophic features in their diaphragm (one of the most affected muscles in this animal model of DMD) [17, 18 ].”
BackgroundEndurance exercise training in myostatin null mice
Savage, K. J., & McPherron, A. C. (2010) · Muscle & Nerve · doi:10.1002/mus.21688 · Cited by 45
The elusive promise of myostatin inhibition for muscular dystrophy
Wagner, K. R. (2020) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000853 · Cited by 51
Hulmi, J. J., Kovanen, V., Lisko, I., Selänne, H., & Mero, A. A. (2007) · European Journal of Applied Physiology · doi:10.1007/s00421-007-0579-4 · Cited by 47
“Myostatin is a TGF- superfamily member (McPherron et al. 1997) and is a negative regulator of muscle mass in humans (Schuelke et al. 2004) and in other mammals ( Bogdanovich et al. 2002; McPherron et al. 1997).”
BackgroundBuilding muscle, browning fat and preventing obesity by inhibiting myostatin
LeBrasseur, N. K. (2012) · Diabetologia · doi:10.1007/s00125-011-2361-8 · Cited by 46
“and disease (cachexia and degeneration) (for examples, see [7–11]).”
BackgroundTGF-β Inhibits Muscle Differentiation by Blocking Autocrine Signaling Pathways Initiated by IGF-II
Gardner, S., Alzhanov, D., Knollman, P. E., Kuninger, D., & Rotwein, P. S. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0292 · Cited by 51
Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy
Lee, Y., Lehar, A., Sebald, S. M., Liu, M., Swaggart, K. A., Talbot, C. C., Pytel, P., Barton, E. R., McNally, E. M., & Lee, S. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv288 · Cited by 47
Self-citationLi, X., Wang, S.-J., Tan, S. C., Chew, P. L., Liu, L., Wang, L., Wen, L., & Ma, L. (2014) · Journal of Sports Sciences · doi:10.1080/02640414.2013.865252 · Cited by 45
“The first postulates that hyperplasia occurs during embryonic development, while hypertrophic occurs during late embryonic and postnatal development (Bogdanovich et al., 2002; McPherron et al., 1997; Whittemore et al., 2003).”
BackgroundAdvances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies
Zheng, Y., Feng, J., Yu, Y., Ling, M., & Wang, X. (2024) · Archives of Pharmacal Research · doi:10.1007/s12272-024-01493-2 · Cited by 50
“…in previous studies that the use of a soluble activin receptor 2B (ACVR2B) to achieve systemic blockade of activin receptor signaling can effectively enhance muscle mass in animal models of cancer cachexia (Zhou et al. 2010), muscular dystrophy (Bogdanovich et al. 2002), and androgen deficiency.”
Bonetto, A., Penna, F., Minero, V. G., Reffo, P., Costamagna, D., Bonelli, G., Baccino, F. M., & Costelli, P. (2010) · Amino Acids · doi:10.1007/s00726-010-0683-3 · Cited by 45
“…in various conditions characterized by muscle atrophy, such as ageing, disuse, sepsis, amyotrophic lateral sclerosis, dystrophy and cancer (Lecker et al., 1999; Bogdanovich et al., 2002; Zimmers et al., 2002; Holzbaur et al., 2006; Costelli et al., 2008; Liu et al., 2008; Bonetto et al., 2009).”
Freire, P. P., Fernández, G. J., Cury, S. S., de Moraes, D., Oliveira, J. S., de Oliveira, G., Dal‐Pai‐Silva, M., Reis, P. P., & Carvalho, R. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081962 · Cited by 48
“This trial showed a potential increase in the muscle size of the subjects, but the researchers observed no improvements in muscle strength or function [52,53].”
BackgroundBish, L. T., Morine, K., Sleeper, M. M., & Sweeney, H. L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010230 · Cited by 49
“mice [16,17,18,19,20,21] as well as by the double-muscled Belgian Blue and Piedmontese cattle breeds [22], which harbor a naturally occurring mutation in the myostatin gene.”
Signal transduction pathways that regulate muscle growth
Wackerhage, H., & Ratkevicius, A. (2008) · Essays in Biochemistry · doi:10.1042/bse0440099 · Cited by 41
“Myostatin is an ideal therapeutic target and monoclonal anti-myostatin antibodies have been developed to this end; these antibodies have been shown to be effective in dystrophic mice [27]; patients with muscular dystrophies are currently recruited for trials with monoclonal anti-myostatin antibodies produced by Wyeth.”
BackgroundRegenerative capacity of the dystrophic (mdx) diaphragm after induced injury
Matecki, S., Guibinga, G.-H., & Petrof, B. J. (2004) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00146.2004 · Cited by 50
“This could consist of a loss of positive stimulatory signals and/or an increase in factors that actively inhibit regeneration or muscle growth (1, 4, 7).”
BackgroundSerra, F., Quarta, M., Canato, M., Toniolo, L., Arcangelis, V. D., Trotta, A., Spath, L., Monaco, L., Reggiani, C., & Naro, F. (2012) · Muscle & Nerve · doi:10.1002/mus.23432 · Cited by 45
Yokota, T., Duddy, W. J., Echigoya, Y., & Kolski, H. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.693469 · Cited by 44
“Since dystrophin was first identified in 1987, many potential therapies including transplantation of stem cells, virus vector-mediated gene therapies and drug therapies such as corticosteroids or myostatin inhibitors have emerged [3-6].”
BackgroundIs Exercise the Right Medicine for Dystrophic Muscle?
Spaulding, H. R., & Selsby, J. T. (2018) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000001639 · Cited by 44
Hoogaars, W. M. H., & Jaspers, R. T. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-1435-3_8 · Cited by 45
Cesari, M., Bernabei, R., Vellas, B. J., Fielding, R. A., Rooks, D., Azzolino, D., Mariani, J., Oliva, A. A., Bhasin, S., & Rolland, Y. (2022) · The Journal of Frailty & Aging · doi:10.14283/jfa.2022.30 · Cited by 53
“(18) showed that the block of myostatin is associated with an increase in muscle mass and strength and a parallel decrease of muscle damage in mice.”
BackgroundApproaching a New Age in Duchenne Muscular Dystrophy Treatment
Wagner, K. R. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.08.013 · Cited by 52
Improved Success of Myoblast Transplantation in mdx Mice by Blocking the Myostatin Signal
Benabdallah, B., Bouchentouf, M., & Tremblay, J. P. (2005) · Transplantation · doi:10.1097/01.tp.0000167379.27872.2b · Cited by 52
“Moreover, blockade of endogenous myostatin with antibodies resulted in increased body weight, muscle mass, muscle size, and absolute muscle strength in mdx mouse muscles (13).”
BackgroundResultEmerging drugs for sarcopenia: age-related muscle wasting
Lynch, G. S. (2004) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.9.2.345 · Cited by 43
“These findings support the notion that myostatin inhibitors could provide a therapeutic benefit in conditions where muscle mass is limiting, including sarcopenia [166,169-171].”
BackgroundUse of evans blue dye to compare limb muscles in exercised young and old mdx mice
Wooddell, C. I., Zhang, G., Griffin, J. B., Hegge, J., Huss, T., & Wolff, J. A. (2009) · Muscle & Nerve · doi:10.1002/mus.21527 · Cited by 43
“a mild shock to encourage continued running,(11,22,23,14) voluntary wheel running in the cage over 24 or 48 hours,(24,16) swimming,(25) and balancing on a rotating rotarod.(26) The cell membrane-impermeable Evans blue dye (EBD) has been used as a tracer to evaluate the vasculature of living animals and the integrity o…”
MethodLamar, K.-M., Bogdanovich, S., Gardner, B. B., Gao, Q. Q., Miller, T., Earley, J. U., Hadhazy, M., Vo, A. H., Wren, L., Molkentin, J. D., et al. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1006019 · Cited by 43
“In mouse models, where myostatin inhibition has been well studied, the increase in muscle mass was associated with an absolute increase in strength or force, rather than an increase in specific force [50].”
BackgroundSelf-citationDesgeorges, M. M., Devillard, X., Toutain, J., Castells, J., Divoux, D., Arnould, D., Haqq, C. M., Bernaudin, M., Durieux, A., Touzani, O., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13912-0 · Cited by 46
Therapy of muscle wasting in cancer: what is the future?
Muscaritoli, M., Bossola, M., Bellantone, R. D. A., & Fanelli, F. R. (2004) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000134366.07148.2e · Cited by 47
Identification of the Minimum Peptide from Mouse Myostatin Prodomain for Human Myostatin Inhibition
Takayama, K., Noguchi, Y., Aoki, S., Takayama, S., Yoshida, M., Asari, T., Yakushiji, F., Nishimatsu, S., Ohsawa, Y., Itoh, F., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501170d · Cited by 43
Expression profiling with progression of dystrophic change in dysferlin-deficient mice (SJL)
Suzuki, N., Aoki, M., Hinuma, Y., Takahashi, T., Onodera, Y., Ishigaki, A., Kato, M., Warita, H., Tateyama, M., & Itoyama, Y. (2005) · Neuroscience Research · doi:10.1016/j.neures.2005.01.006 · Cited by 44
Yang, X., Koltes, J. E., Park, C. A., Chen, D., & Reecy, J. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117607 · Cited by 44
“Previous studies have demonstrated that MSTN blockade can functionally improve dystrophic muscle [4] and that MSTN can also play an important role in adipose development [5].”
BackgroundAnti-cytokine strategies for the treatment of cancer-related anorexia and cachexia
Penna, F., Minero, V. G., Costamagna, D., Bonelli, G., Baccino, F. M., & Costelli, P. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.503773 · Cited by 41
“Myostatin activity can be inhibited pharmacologically by several compounds such as neutralizing antibodies, myostatin propeptide or soluble activin receptor [35-37].”
BackgroundSilencing Nfix rescues muscular dystrophy by delaying muscle regeneration
Rossi, G., Bonfanti, C., Antonini, S., Bastoni, M., Monteverde, S., Innocenzi, A., Saclier, M., Taglietti, V., & Messina, G. (2017) · Nature Communications · doi:10.1038/s41467-017-01098-y · Cited by 42
Morgoulis, D., Berenstein, P., Cazacu, S., Kazimirsky, G., Dori, A., Barnea, E. R., & Brodie, C. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1307-9 · Cited by 45
Jin, Q., Qiao, C., Li, J., Xiao, B., Li, J., & Xiao, X. (2019) · Skeletal Muscle · doi:10.1186/s13395-019-0197-y · Cited by 45
Forcales, S. V., & Puri, P. (2005) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2005.07.005 · Cited by 49
Quantitative trait loci for human muscle strength: linkage analysis of myostatin pathway genes
Huygens, W., Thomis, M. A., Peeters, M., Aerssens, J., VLIETINCK, R. F., & Beunen, G. P. (2005) · Physiological Genomics · doi:10.1152/physiolgenomics.00010.2005 · Cited by 45
“Recently, a few studies blocking myostatin with antibodies in adult mice showed an increase in muscle growth and strength and a reduced muscle wasting in dystrophic muscles (6, 42, 43), which makes the myostatin pathway an interesting pharmacological target.”
Gene therapy for muscular dystrophy ? a review of promising progress
Gregorevic, P., & Chamberlain, J. S. (2003) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.3.5.803 · Cited by 45
“Additionally, heavily deleted Ad vectors are among the few viral vehicles capable of packaging the entire dystrophin and utrophin coding sequence, and with gutted models capable of packaging almost 30 kb of DNA, increasingly advanced designs may utilise Ad vectors to co-deliver improved regulatory elements, immunomodu…”
BackgroundTsuchida, K. (2008) · PubMed Central · Cited by 51
Inhibition of myostatin improves muscle atrophy in oculopharyngeal muscular dystrophy (OPMD)
Harish, P., Malerba, A., Lu‐Nguyen, N., Forrest, L., Cappellari, O., Roth, F., Trollet, C., Popplewell, L. J., & Dickson, G. (2019) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12438 · Cited by 43
Hoogaars, W. M. H., Mouisel, É., Pasternack, A. H., Hulmi, J. J., Relizani, K., Schuelke, M., Schirwis, E., García, L., Ritvos, O., Ferry, A., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.056 · Cited by 43
“…methods including sActRIIB-Fc showed that Mstn blockade in mdx mice stimulated muscle growth and strength, and some reports indicated an alleviated dystrophic phenotype (Bogdanovich et al. , 2002, 2005; Haidet et al. , 2008; Morine et al. , 2010; Nakatani et al. , 2008; Pistilli et al. , 2011).”
Diel, P. R., Schiffer, T., Geisler, S., Hertrampf, T., Mosler, S., Schulz, S., Wintgens, K. F., & Adler, M. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.08.015 · Cited by 41
“Blocking of the MSTN signalling transduction pathway by specific inhibitors and genetic manipulations has been shown to result in a dramatic increase of skeletal muscle mass (Bogdanovich et al. 2002; Whittemore et al. 2003; Bogdanovich et al. 2005).”
BackgroundDoping and musculoskeletal system: short‐term and long‐lasting effects of doping agents
Nikolopoulos, D., Spiliopoulou, C., & Theocharis, S. E. (2010) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2010.00881.x · Cited by 61
A proposed nomenclature consensus for the myostatin gene family
Rodgers, B. D., Roalson, E. H., Weber, G. M., Roberts, S., & Goetz, F. W. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00395.2006 · Cited by 42
Role of IGF-I in follistatin-induced skeletal muscle hypertrophy
Barbé, C., Kalista, S., Loumaye, A., Ritvos, O., Lause, P., Ferracin, B., & Thissen, J.-P. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00098.2015 · Cited by 38
“The possibility that this decrease in muscle IGF-I peptide results from a decrease in extracellular matrix as observed in response to Mstn inhibition (9, 10, 60) is unlikely.”
BackgroundBaligand, C., Gilson, H., Ménard, J., Schakman, O., Wary, C., Thissen, J. P., & Carlier, P. G. (2009) · Gene Therapy · doi:10.1038/gt.2009.141 · Cited by 41
Spinazzola, J. M., & Kunkel, L. M. (2016) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2016.1240613 · Cited by 41
“Three months of weekly injections increased muscle mass up to 35% due to fiber size enlargement, and strikingly, serum creatine kinases levels decreased to near normal levels [45].”
BackgroundShi, S., Hoogaars, W. M. H., de Gorter, D. J. J., van Heiningen, S. H., Lin, H. Y.-F., Hong, C. C., Kemaladewi, D. U., Aartsma-Rus, A. M., ten Dijke, P., & Hoen, P. A. C. ’. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.10.003 · Cited by 43
Identification of gene expression modifications in myostatin-stimulated myoblasts
Yang, W. Z., Zhang, Y., Ma, G., Zhao, X., Chen, Y., & Zhu, D. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.096 · Cited by 41
Administration of myostatin does not alter fat mass in adult mice
Stolz, L. E., Li, D., Qadri, A., Jalenak, M., Klaman, L. D., & Tobin, J. F. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00672.x · Cited by 39
Myostatin inhibits proliferation of human urethral rhabdosphincter satellite cells
Akita, Y., Sumino, Y., Mori, K., Nomura, T., Sato, F., & Mimata, H. (2012) · International Journal of Urology · doi:10.1111/j.1442-2042.2012.03186.x · Cited by 39
Xu, L., Zhao, P., Mariano, A., & Han, R. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.39 · Cited by 40
Patruno, M., Caliaro, F., Maccatrozzo, L., Sacchetto, R., Martinello, T., Toniolo, L., Reggiani, C., & Mascarello, F. (2007) · Differentiation · doi:10.1111/j.1432-0436.2007.00189.x · Cited by 44
Regenerative pharmacology in the treatment of genetic diseases: The paradigm of muscular dystrophy
Mozzetta, C., Minetti, G., & Puri, P. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.08.033 · Cited by 43
Yaden, B. C., Wang, Y. X., Wilson, J. M., Culver, A. E., Milner, A., Datta‐Mannan, A., Shetler, P. K., Croy, J. E., Dai, G., & Krishnan, V. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.12.029 · Cited by 42
Lu‐Nguyen, N., Malerba, A., Popplewell, L. J., Schnell, F., Hanson, G. J., & Dickson, G. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2016.11.009 · Cited by 39
Facioscapulohumeral Muscular Dystrophies
Wagner, K. R. (2019) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000801 · Cited by 39
Herbelet, S., Rodenbach, A., Paepe, B. D., & Bleecker, J. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134596 · Cited by 39
“All clinical trials (NCT02310763 and NCT02907619) were abrogated in 2018 due to a lack of effectiveness [71,76,78,98].”
BackgroundLi, Z., Zhao, B., Kim, Y., Hu, C. Y., & Yang, J. (2009) · Molecular Reproduction and Development · doi:10.1002/mrd.21111 · Cited by 48
“…such as its propeptide, antibody, and truncated activin type IIB receptor to wild-type mice and muscular dystrophic mice 2009 WILEY-LISS, INC. caused significant increase in skeletal muscle mass (Bogdanovich et al., 2002, 2005; Whittemore et al., 2003; Wolfman et al., 2003; Welle et al., 2007).”
BackgroundSB431542 treatment promotes the hypertrophy of skeletal muscle fibers but decreases specific force
Watt, K. I., Jaspers, R. T., Atherton, P., Smith, K., Rennie, M. J., Ratkevičius, A., & Wackerhage, H. (2010) · Muscle & Nerve · doi:10.1002/mus.21573 · Cited by 41
“Previously published reports have shown that longterm inhibition of myostatin signaling results in hypertrophy of fibers in mature skeletal muscle.(9,10,12,13,26) However, some studies that have assessed force-generating capacity of these enlarged muscles reported a decrease in specific force production.”
BackgroundNoninvasive monitoring of therapeutic gene transfer in animal models of muscular dystrophies
Bartoli, M., Poupiot, J., Goyenvalle, A., Perez, N., García, L., Danos, O., & Richard, I. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302594 · Cited by 39
Glucocorticoids counteract hypertrophic effects of myostatin inhibition in dystrophic muscle
Hammers, D. W., Hart, C. C., Patsalos, A., Matheny, M. K., Wright, L. A., Nagy, L., & Sweeney, H. L. (2019) · JCI Insight · doi:10.1172/jci.insight.133276 · Cited by 38
“Additional studies using genetic ablation (21, 22) and Mstn neutralizing 77 antibodies (23) have also shown beneficial effects of Mstn inhibition for DMD models, and there 78 are currently several Mstn-targeting pharmaceutical products in clinical development (24-29).”
BackgroundMechanisms of myostatin and activin A accumulation in chronic kidney disease
Bataille, S., Dou, L., Bartoli, M., Sallée, M., Aniort, J., Ferkak, B., Chermiti, R., McKay, N., Silva, N. D., Burtey, S., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac136 · Cited by 40
Foster, K., Graham, I. R., Otto, A., Foster, H., Trollet, C., Yaworsky, P. J., Walsh, F. S., Bickham, D. C., Curtin, N. A., Kawar, S. L., et al. (2009) · Rejuvenation Research · doi:10.1089/rej.2008.0815 · Cited by 41
Identification of serum protein biomarkers for utrophin based DMD therapy
Guiraud, S., Edwards, B., Squire, S. E., Babbs, A., Shah, N., Berg, A., Chen, H., & Davies, K. E. (2017) · Scientific Reports · doi:10.1038/srep43697 · Cited by 43
Genetic modifiers of D uchenne and facioscapulohumeral muscular dystrophies
Hightower, R. M., & Alexander, M. S. (2017) · Muscle & Nerve · doi:10.1002/mus.25953 · Cited by 36
“Pharmacological blockade of myostatin or the myostatin receptor activin IIB similarly demonstrated a physiological benefit in protecting against muscle force loss in dystrophic mice.(133,134) A recent clinical trial involving a soluble form of the human activin receptor type IIB (ACE-031; Acceleron Pharma, Boston, MA)…”
An Overview of Recent Therapeutics Advances for Duchenne Muscular Dystrophy
Mah, J. K. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7374-3_1 · Cited by 36
Targeting TGF-β Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-β Type I Receptor
Kemaladewi, D. U., Pasteuning, S., van der Meulen, J. W., van Heiningen, S. H., van Ommen, G. B., ten Dijke, P., Aartsma-Rus, A. M., Hoen, P. A. C. ’., & Hoogaars, W. M. H. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.7 · Cited by 40
Therapeutic prospects to treat skeletal muscle wasting in COPD (chronic obstructive lung disease)
Hansen, M. J., Gualano, R. C., Bozinovski, S., Vlahos, R., & Anderson, G. P. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.007 · Cited by 40
Ubiquitous Gasp1 overexpression in mice leads mainly to a hypermuscular phenotype
Monestier, O., Brun, C. E., Heu, K., Passet, B., Malhouroux, M. M., Magnol, L., Vilotte, J., & Blanquet, V. (2012) · BMC Genomics · doi:10.1186/1471-2164-13-541 · Cited by 37
“The identification of several components of the myostatin-signalling pathway had important implications with respect for testing the therapeutic value of a myostatin antagonist in muscle wasting disorders such as Duchenne muscular dystrophy [22,23] cachexia and age-related sarcopenia [24-26].”
BackgroundSmith, I. J., Aversa, Z., Alamdari, N., Petkova, V., & Hasselgren, P.-O. J. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22796 · Cited by 40
“If that is the case, inhibition of the myostatin pathway, as has been suggested in other catabolic conditions [Bogdanovich et al., 2002; Wagner, 2005; Carnac et al., 2006; Haidet et al., 2008; Tsuchida et al., 2008], may prove beneficial in sepsis despite unchanged myostatin protein levels in…”
BackgroundResultCastillero, E., Akashi, H., Najjar, M., Ji, R., Brandstetter, L. M., Wang, C. K., Liao, X., Zhang, X., Sperry, A., Gailes, M., et al. (2019) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00302.2019 · Cited by 36
Short bouts of stretching increase myo‐D, myostatin and atrogin‐1 in rat soleus muscle
Peviani, S. M., Gomes, A. R. S., Moreira, R. F. C., Moriscot, A. S., & Salvini, T. F. (2006) · Muscle & Nerve · doi:10.1002/mus.20695 · Cited by 43
Metadata
- Authors
- Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S.
- Affiliations
- University of Pennsylvania (US)
- Pfizer (United States) (US)
- Corresponding author
- Khurana, Tejvir S.
- Venue
- Nature
- Published
- 2002-11
- Volume
- 420
- Issue
- 6914
- Pages
- 418-421
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2083700023
- Semantic Scholar
- 590fb54cd1f2d89d44f4e1ad999be802dc756277
- Cited by
- 831
- References
- 31
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 19 · 2023: 15 · 2022: 21 · 2021: 20 · 2020: 23 · 2019: 32 · 2018: 23 · 2017: 34 · 2016: 28 · 2015: 43 · 2014: 34 · 2013: 38 · 2012: 48
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Keywords
- myostatin, Duchenne muscular dystrophy, mdx mice, muscle atrophy, blocking antibodies, muscle mass, muscle strength, muscle degeneration, creatine kinase, TGF-beta superfamily, skeletal muscle growth
- MeSH terms
- Animals, Antibodies, Body Weight, Creatine Kinase, Male, Muscular Dystrophy, Animal, Organ Size, Transforming Growth Factor beta, Mice, Inbred mdx, Muscle, Skeletal, Muscle Fibers, Skeletal, Muscular Dystrophy, Duchenne, Mice, Myostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.